4 Largecap Promoter Backed One-Year Winner Stocks to Watch for Future Multibagger Potential: Divi’s Labs, Torrent Pharma, BHEL and HDFC Life
- November 5, 2026
- Posted by: Manan Bisht
- Category: Best Stocks
Divi’s Labs Rs 10,037.50. Torrent Pharma Rs 4,738.50. BHEL Rs 423.85. HDFC Life Rs 532.50. Market caps from Rs 1.15 lakh crore to Rs 2.63 lakh crore. Data as of 4 Nov 2026.
Quick Answer
Divi’s Labs, Torrent Pharma, BHEL and HDFC Life are the 4 picks in this promoter backed one-year winner stocks watchlist, with market caps between Rs 1.15 lakh crore and Rs 2.63 lakh crore. Divi’s Labs stands out for the largest market cap at Rs 2,62,914 crore, while Torrent Pharma offers the highest return on equity at 25.49%. PE ratios run from 55.85 to 89.89, so compare each one with its industry PE before investing. All figures are as of 4 November 2026.
Promoter backed one-year winner stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Divi’s Labs, Torrent Pharma, BHEL and HDFC Life meet that test, with market caps from Rs 1.15 lakh crore to Rs 2.63 lakh crore and Divi’s Labs offering the largest market cap at Rs 2,62,914 crore. Each of these companies has a promoter holding of at least 50 per cent and a one-year share price return of at least 25 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.
This list covers companies with a promoter holding of at least 50 per cent and a one-year share price return of at least 25 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, market capitalisation above Rs 1,00,000 crore, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening promoter backed one-year winner stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 4 November 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are Promoter Backed One-Year Winner Stocks and Why Do They Attract Multibagger Interest?
Promoter backed one-year winner stocks are shares of large companies in which the promoters own at least half of the business and which have gained at least a quarter in value over the last year. The four here cover pharmaceutical ingredients, branded pharmaceuticals, heavy electrical equipment and life insurance.
Owners with a large stake have their own wealth tied to the company, so a strong one year run in such a company shows that the market agrees with the owners about the business. For promoter backed one-year winner stocks, both FY26 and the latest quarter showed growth. For promoter backed one-year winner stocks, checking each result against the latest quarter matters more than any single ratio. The next sections explain what stands out in each of promoter backed one-year winner stocks, using FY26 and latest quarter data. Prices move daily, so recheck the figures for promoter backed one-year winner stocks before you decide.
Promoter Backed One-Year Winner Stocks at a Glance: Price, Market Cap, PE, ROE and Price to Book
Prices are closing prices as of 4 November 2026. BHEL has the lowest PE of the group at 55.85, while Torrent Pharma posts the highest return on equity at 25.49%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Price to Book | 52-Week Range (Rs) |
|---|---|---|---|---|---|---|---|
| Divi’s Laboratories | 10,037.50 | 2,62,914 | 89.89 | 36.42 | 15.32% | 15.69 | 5,647.50 to 10,064.00 |
| Torrent Pharmaceuticals | 4,738.50 | 1,79,873 | 83.43 | 36.42 | 25.49% | 21.39 | 3,480.60 to 5,250.00 |
| Bharat Heavy Electricals | 423.85 | 1,60,832 | 55.85 | 45.89 | 10.76% | 6.01 | 229.54 to 464.00 |
| HDFC Life Insurance | 532.50 | 1,15,293 | 58.38 | 10.47 | 10.10% | 5.89 | 385.50 to 688.00 |
Divi’s Labs: Debt-to-Equity of 0.00
Divi’s Laboratories makes active pharmaceutical ingredients and intermediates and runs a large custom synthesis business for global drug companies. It reported FY26 revenue of Rs 11,067 crore, up 13.95% year on year, and net profit of Rs 2,568 crore, up 17.21%. Revenue has compounded at 5.09% a year since FY22. Operating margin was 36.70% in FY26. The debt-to-equity ratio is 0.00, which keeps interest costs low.
In the June 2026 quarter, revenue rose 24.32% to Rs 3,144 crore and net profit grew 65.50% to Rs 902 crore. The share price has gained 70.59% over five years and 38.07% over the past year. Foreign investors raised their holding from 19.39% in September 2025 to 20.38% in September 2026. The stock trades at a PE of 89.89 against an industry PE of 36.42, with a return on equity of 15.32%.
Torrent Pharma: 28.79% Profit CAGR Since FY22
Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.
The stock trades at a PE of 83.43 against an industry PE of 36.42, with a return on equity of 25.49%. In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 200.24% over five years and 32.19% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026.
BHEL: 37.73% Profit CAGR Since FY22
Bharat Heavy Electricals is a government-owned maker of power generation, transmission, industrial and transportation equipment. It reported FY26 revenue of Rs 34,589.83 crore, up 20.08% year on year, and net profit of Rs 1,600.26 crore, up 199.73%. Net profit has compounded at 37.73% a year since FY22, while revenue has grown 12.54% a year. Operating margin was 10.18% in FY26. The debt-to-equity ratio is 0.23.
In the September 2026 quarter, revenue rose 24.28% to Rs 9,553.01 crore and net profit grew 118.98% to Rs 820.94 crore. The share price has gained 523.42% over five years and 97.23% over the past year. Domestic institutions raised their holding from 18.62% in September 2025 to 21.88% in September 2026. The stock trades at a PE of 55.85 against an industry PE of 45.89.
HDFC Life: Profit Compounding at 9.57% a Year
HDFC Life Insurance is one of the largest private life insurers in India and sells protection, savings, annuity and pension plans. It reported FY26 total income of Rs 1,00,355.41 crore, up 3.05% year on year, and net profit of Rs 1,912.32 crore, up 5.61%. Net profit has compounded at 9.57% a year since FY22, while total income has grown 10.26% a year.
The stock trades at a PE of 58.38 against an industry PE of 10.47. In the September 2026 quarter, total income rose 18.63% to Rs 24,683.29 crore and net profit grew 16.35% to Rs 521.60 crore. The share price is up 31.99% over the past year. Domestic institutions raised their holding from 14.58% in June 2025 to 20.19% in June 2026.
Promoter Backed One-Year Winner Stocks: Financial Comparison on Growth and Margins
The table compares scale and growth across these promoter backed one-year winner stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | Revenue Growth (YoY) | 4-Year Revenue CAGR | Latest Quarter Revenue Growth |
|---|---|---|---|---|---|
| Divi’s Labs | 11,067 | 2,568 | 13.95% | 5.09% | 24.32% |
| Torrent Pharma | 13,886.15 | 2,138.18 | 20.34% | 12.38% | 56.29% |
| BHEL | 34,589.83 | 1,600.26 | 20.08% | 12.54% | 24.28% |
| HDFC Life | 1,00,355.41 | 1,912.32 | 3.05% | 10.26% | 18.63% |
Check the Univest Screener for live data on these promoter backed one-year winner stocks
Institutional Holding in Divi’s Labs, Torrent Pharma, BHEL and HDFC Life
Institutional holding shows who is backing these promoter backed one-year winner stocks alongside the promoter. The table uses the latest reported quarter for each. Divi’s Labs has the deepest institutional backing, with FII and DII together holding 39.55% as of September 2026. Domestic institutions increased their holding over the past year in Torrent Pharma (from 9.28% to 12.87%), BHEL (from 18.62% to 21.88%) and HDFC Life (from 14.58% to 20.19%).
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| Divi’s Labs | 51.88% | 20.38% | 19.17% | 8.58% | September 2026 |
| Torrent Pharma | 60.78% | 17.97% | 12.87% | 8.38% | July 2026 |
| BHEL | 58.17% | 9.94% | 21.88% | 10.02% | September 2026 |
| HDFC Life | 50.54% | 19.27% | 20.19% | 10.01% | June 2026 |
Risks to Weigh in Promoter Backed One-Year Winner Stocks
Being careful with promoter backed one-year winner stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Past growth may not repeat.
- Share prices can move sharply in either direction.
- Valuation: HDFC Life trades at a PE of 58.38 against an industry PE of 10.47, so earnings need to keep growing to support the price.
- Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.
How to Choose Between Promoter Backed One-Year Winner Stocks
Picking from promoter backed one-year winner stocks comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (10.47 to 45.89) and ask whether the growth rate justifies any gap.
- Track net profit growth, the operating margin and the return on equity in every quarterly result.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track Divi’s Labs, Torrent Pharma, BHEL and HDFC Life live prices.
Conclusion
Among promoter backed one-year winner stocks, Divi’s Labs stands out for the largest market cap at Rs 2,62,914 crore, Torrent Pharma for the highest return on equity at 25.49%, BHEL for the fastest profit growth, 37.73% a year since FY22 and HDFC Life for 3.05% revenue growth in FY26. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing promoter backed one-year winner stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Promoter Backed One-Year Winner Stocks to Watch
Which are the best promoter backed one-year winner stocks to watch for multibagger potential?
Ans. Divi’s Labs, Torrent Pharma, BHEL and HDFC Life are the 4 names this list highlights, with market caps of Rs 2,62,914 crore, Rs 1,79,873 crore, Rs 1,60,832 crore and Rs 1,15,293 crore respectively. Divi’s Labs is notable for the largest market cap at Rs 2,62,914 crore. Torrent Pharma stands out for the highest return on equity at 25.49%. BHEL offers the fastest profit growth, 37.73% a year since FY22. HDFC Life brings 3.05% revenue growth in FY26. These are watchlist names for promoter backed one-year winner stocks, not recommendations, so match each one to your own risk profile and time horizon.
Is Torrent Pharma a good stock for long-term investors?
Ans. Torrent Pharma has a return on equity of 25.49%, a PE of 83.43 against an industry PE of 36.42 and a market cap of Rs 1,79,873 crore. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34% while June 2026 quarter net profit grew 3.28%. Long-term returns in promoter backed one-year winner stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can BHEL become a multibagger from here?
Ans. BHEL has already gained 523.42% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in promoter backed one-year winner stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 37.73% a year since FY22, and FY26 revenue rose 20.08%. At a PE of 55.85 against an industry PE of 45.89, valuation should be checked against that growth before investing.
What is the market cap of Divi’s Labs, Torrent Pharma, BHEL and HDFC Life?
Ans. As of 4 November 2026, Divi’s Labs has a market cap of Rs 2,62,914 crore, Torrent Pharma has a market cap of Rs 1,79,873 crore, BHEL has a market cap of Rs 1,60,832 crore and HDFC Life has a market cap of Rs 1,15,293 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on promoter backed one-year winner stocks.
What are the risks of investing in promoter backed one-year winner stocks?
Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. HDFC Life trades at a PE of 58.38 against an industry PE of 10.47, so earnings growth needs to hold up.
Why is HDFC Life trading at a PE of 58.38?
Ans. HDFC Life’s PE of 58.38 compares with an industry PE of 10.47. The market is paying a premium for latest-quarter profit growth of 16.35%, which also means the stock is more sensitive if growth slows. Investors in promoter backed one-year winner stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.
How much do institutions hold in Divi’s Labs, Torrent Pharma, BHEL and HDFC Life?
Ans. As of the latest reported quarter, FII and DII together hold 39.55% of Divi’s Labs (20.38% and 19.17%), 30.84% of Torrent Pharma (17.97% and 12.87%), 31.82% of BHEL (9.94% and 21.88%) and 39.46% of HDFC Life (19.27% and 20.19%). Rising institutional holding is a useful signal in promoter backed one-year winner stocks, though it should be read with earnings trends rather than on its own.
